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CHAPTER 1 INTRODUCTION
1.1. Background
Cancer is accountable for millions of deaths annually worldwide. According
to the American Cancer Society, cancer is the second most common cause of
death in the United States. Approximately 1.7 million new cancer cases are
expected and about 600,000 Americans are expected to die of cancer in 2016 [1].
Chemotherapy, radiotherapy, and photothermal therapy are the most common
treatments for cancer. Chemotherapy is the most common strategy in cancer
treatment because of its higher efficacy as compared to other types of treatments
[2–5]. In most cases, cancer diagnosis in the early stage is difficult. Most of the
patients are diagnosed at the late stage of cancer with a poor prognosis. In the
advanced stage of cancer, chemotherapy and radiotherapy are the only options.
However, the development of chemotherapeutic drug resistance is the most
common reason leading to the failure of cancer treatment. The conventional
treatment with the systemic distribution of chemotherapeutics is problematic and
shows a significant flow that can make the difference between success and failure
[6]. High doses are often required to accumulate adequate amounts of
chemotherapeutic agents at the tumor site to achieve desirable therapeutic
efficacy. However, larger doses possess a higher risk of adverse side-effects with
the increase of toxicity in non-targeted sites or normal tissues. The bleak prognosis
for patients diagnosed with metastatic cancer along with the low therapeutic
efficacy and the recurrence of cancer in conventional chemotherapy are prompting
clinical medicine to adopt a new strategy to detect cancer in early stage and to
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deliver the anticancer drugs specifically to tumor site to enhance therapeutic
efficiency and minimize side effects.

1.2. CDF (3,4-difluorobenzylidene diferuloylmethane) – a highly
potent but extremely lipophilic anticancer drug
In our earlier studies 3,4-difluorobenzylidene diferuloylmethane (CDF), a
synthetic analog of a potent flavonoid anticancer compound has shown 16-fold
increased half-life and high anticancer activity compared to its natural analog,
diferuloylmethane when tested on pancreatic cancer cells [7–9]. The observed
improvement in properties of CDF was attributed to its much higher stability and
bioavailability compared to the natural counterpart. CDF could inhibit the growth of
cancer cells through down-regulation of multiple miRNAs, up-regulation of
phosphatase and tensin homolog (PTEN), and attenuation of histone
methyltransferase EZH2 [10–12]. These findings strongly indicate that CDF could
be a good candidate for several cancers, including cervical cancer. However, one
significant problem limiting CDF from further preclinical and clinical testing is its
very poor aqueous solubility. In our previous studies, we successfully overcame
CDF’s solubility problem by using dendrimer and micellar nanocarriers [7,13]. In
those studies, CDF has shown a significant anticancer activity on tested cancer
cells including triple marker positive stem-like pancreatic cancer cells.

3

1.3. Polyamidoamine (PAMAM) dendrimers in targeted drug
delivery
1.3.1. What are PAMAM dendrimers?
PAMAM dendrimers are a relatively novel class of polymers with a welldefined, nano-sized, highly branched and monodispersed structures with
numerous hydrophilic reactive amine groups on the periphery and lipophilic
internal cavities. PAMAM dendrimers are known for their ability to encapsulate
hydrophobic drugs in their internal cavities to enhance the aqueous solubility of
these hydrophobic compounds [14–16]. The larger numbers of reactive amine
groups on the periphery makes PAMAM dendrimers suitable for many biomedical
applications such as drug conjugation, siRNA and gene complexation, and
conjugation to bio-recognition molecules to achieve active targeting ability [17,18].
When PAMAM dendrimers are used as drug carriers, they can enhance the drug
biodistribution in tumor site possibly by taking the advantage of enhanced
permeation and retention effect [19–21]. In addition, it is demonstrated that by
carrying targeting ligands on the surface, PAMAM dendrimers can achieve active
receptor targeting. In this regards, one of the most commonly used targeting
ligands is folic acid (FA). Many types of cancer cells (such as ovarian, colon, lung,
breast and cervical cancer cells) are known to have a high expression of folate
receptors on their membranes [22–25]. Drug carriers decorated with FA can
achieve targeting ability and high accumulation in cancer cells by taking advantage
of the specific binding of FA with folate receptors overexpressed on these targeted
cancer cells. Cellular internalization is facilitated via folate-receptor mediated
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endocytosis and followed by the release of anticancer drug; thus, resulting in a
better accumulation with minimized toxicity to normal cells.

1.3.2. Dendrimer mediated tumor targeted delivery: Passive and active
targeting
1.3.2.1.

Dendrimer-mediated passive targeting strategy

The passive targeting pathway of dendrimers utilizes the inherent ability of
macromolecules to extravasate and accumulate specifically in the tumor
microenvironment based on a phenomenon called the enhanced permeability and
retention (EPR) effect, which was discovered by Matsumura and Maeda [19]. The
EPR phenomenon suggested that the rapid proliferation of tumor cells create
complex networks of blood vessels that are highly disorganized and leaky. The
dilation of blood vessels is facilitated by excessive levels of vascular permeability
mediators

secreted

by

tumor

cells

[4,26–28].

The

anatomical

and

pathophysiological abnormalities in tumor environment result in an extensive
leakage of macromolecules and nanoparticles including dendrimers into the tumor
interstitium [26,28–30]. In addition, the lymphatic clearance in solid tumors is
dysfunctional in general. As a consequence, drugs conjugated or encapsulated in
macromolecules and nanoparticles can attain very high local concentrations in the
tumor environment with negligible accumulation in the non-targeted or healthy
organs. Particle size is an important factor dictating the localization and retention
in tumor tissues. It is observed that nanoparticles in the range of ten to a few
hundred nanometers can exploit the EPR phenomenon to accumulate in tumor
tissues [31]. In this regards, dendrimers with a typical size range from 10 to 20 nm
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are favorable to achieve passive tumor targeting [32]. In addition, dendrimers have
prolonged half-life in the systemic circulation and can avoid renal excretion due to
the ability to bind to plasma proteins and biomolecules [33]. As a result, dendrimers
can retain in the blood for an extended duration and accumulate in the tumor
environment by EPR effect, suggesting a sustained and controlled delivery profile.
1.3.2.2.

Dendrimer-mediated active targeting strategy

The passive tumor targeting has numerous challenges due to the
complexity of the anatomic and pathophysiological barriers in the in vivo biological
environment. The passive targeting strategy is only effective in highly permeable
solid tumors. In most cases, the permeability in tumors is relatively poor and nonuniform; thus, it is difficult to take advantage of EPR effect in these heterogeneous
and impermeable tumors [34]. These limitations can be resolved to some extent
by utilizing the active targeting strategy, a phenomenon where specific targeting
ligands are introduced to the nanostructure to facilitate the selective binding to
unique and overexpressed receptors on specific tumor cells. In this regards,
dendrimers with numerous reactive functional groups on the periphery are
favorable for the conjugation with targeting ligands for the active targeting effect.
Folic acid is one of the most common targeting ligands for several reasons.
Folic acid is a low molecular weight B-vitamin whose receptors are found to be
overexpressed in numerous types of cancer cells, including lung, breast, colon,
choroid plexus brain, choriocarcinoma, cervical, and ovarian cancers [22,24,35].
Folate receptors are known to occur in clusters, giving the ability to enhance
targeting efficacy by using multiple folic acid moieties on nanoparticles. Many types
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of cancer cells are known to have a high level expression of folate receptors.
Healthy cells also express folate receptors but with a significantly lower degree.
Moreover, folate receptors in healthy cells are in a different location which is not
accessible from the bloodstream, suggesting that folate receptors in cancer cells
could be a perfect target for actively targeted drug delivery [22].
Because of the small size, folic acid is known to be a stable molecule that
does not induce an immune response. As compared to an antibody, folic acid is a
better targeting ligand since its binding affinity to folate receptors is not diminished
after its conjugation to macromolecules or nanoparticles [36,37]. In addition,
antigen expression may change over time; whereas, folate receptors are stable
because folic acid is a crucial ingredient in biosynthesis needed for cellular
proliferation [37–39]. After the binding of the folate-decorated nanoparticles,
endocytosis will occur resulting in the internalization of the folate-decorated
nanoparticles. Then, folate receptors are recycled to the cell surface and ready for
binding with the next nanoparticles [40].

1.4. Biomedical application of Magnetic Resonance Imaging
1.4.1. Magnetic resonance imaging (MRI)
MRI is one of the most common clinical diagnostic tools due to its
noninvasive, tomographic properties that offers superb spatial resolution without
the dangers of ionizing radiation. Hydrogen nuclei or protons in water molecules
are the main contributors to MRI signal in biological applications. In a simplistic
sense, MR imaging is just the proton nuclear magnetic resonance (NMR) in the
biological systems which yields the intensity maps of the proton relaxation time in
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tissue [41]. The difference in the proton density and the relaxation time constants
in the tissue samples gives the contrast in the resulting MR images. However, the
sensitivity of the MR images is relatively low if we only rely upon these inherent
contrast mechanisms [42]. This limitation can be addressed by using exogenous
magnetic agents or contrast agents which can influence the spin relaxation time of
the local protons thereby enhancing the contrast in the resulting MR images [43–
46].

1.4.2. MRI contrast agents
Among several types of contrast agents, the two major classes are chelated
paramagnetic ions such as Gadolinium (Gd), and superparamagnetic iron oxide
nanoparticles (SPIONs). SPIONs have several advantages as compared to
chelated paramagnetic ions. SPIONs are detectable at nM concentrations or lower,
whereas chelated paramagnetic ions detection concentration is at the mM in order
to generate adequate contrast [47]. In addition, paramagnetic chelates need the
exchange of water protons in order to produce local contrast effects; whereas,
SPIONs can impact a larger region of tissue without the direct contact with water
protons by producing magnetic field gradients [39,45,48].
In recent years, magnetic nanoparticles are getting more attention due to
their applications in biology and medicine such as enzyme and protein
immobilization, magnetic resonance imaging, tissue engineering, magnetic cell
tracking and separation, hyperthermia, and targeted drug and gene delivery
[49,50]. Drug delivery systems based on magnetic nanoparticle carriers possess
the ability of magnetic resonance imaging contrast agents as well as the advanced
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properties of nanocarriers such as the enhanced aqueous solubility, increased
systemic circulation time, targeting delivery of chemotherapeutic drugs with
reduced toxicity in normal tissues. Magnetic iron oxide (Fe 3O4) nanoparticles,
especially superparamagnetic iron oxide nanoparticles, have been widely studied
and shown great potentials in biotechnology because of their biocompatible, inert,
and excellent superparamagnetism properties [51,52]. In in vivo applications, the
surface of these magnetic nanoparticles can be modified with polymeric shells
such as dextran, PEG, chitosan, and dendrimers [53–55]. These polymeric shells
provide not only the biocompatibility for the magnetic nanoparticles, but also the
ability for conjugation with biomolecules such as proteins, nucleic acids, enzymes,
targeting ligands, and drugs [56–59].

1.4.3. Iron oxide nanoparticles – Safe and highly effective MRI contrast
agents
There are many factors that make iron oxide Fe 3O4 excellent MRI contrast
agents. Iron oxide particles occur naturally in many animals and are currently the
only inorganic contrast particles approved for in vivo human applications
(Endorem® or Feridex I.V.®; Advanced Magnetics, Cambridge, Massachusetts,
USA) [39,60,61]. Iron oxide particles are biodegradable without either acute or
chronic toxicity [62–65]. Uncoated magnetic iron oxide particles have an LD 50 of
300 to 600 mg iron per kg body weight, and the surface coating has shown to be
able to improve the biocompatibility of the iron oxides by an order of magnitude
[39,66]. The typical clinical dose for SPIONs is 1 mg Fe per kg body weight which
is significantly lower than LD50. It is also a small fraction of the approximately 3500
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mg of total iron in various forms naturally found in the human body. In addition,
many studies have shown that the human body has established methods to
metabolize the excess amount of iron introduced by the particles [48,64,67,68].
SPIONs have been studied with many different agents for actively targeted
MRI. In a study by Cheon et al., SPIONs were modified with dimercaptosuccinic
acid, followed by the conjugation of Herceptin molecules via the free thiol functional
groups on the particles. The targeting ability of the particles was demonstrated in
vitro with different cell lines with a different level of her2/neu expression. The
results showed a decrease in MRI signal intensity with the increase of the
expression of her2/neu. In in vivo studies using mice bearing a NIH3T6.7
xenograft, SPIONs conjugated Herceptin showed an enhanced contrast in MR
signal as compared to SPIONs conjugated with the irrelevant antibodies [69].
Besides antibody, transferrin has been used as a targeting ligand for SPIONs
[38,70]. Many studies have suggested that SPIONs decorated transferrin could
benefit from the transferrin receptor-mediated endocytosis, resulting in a higher
degree of cellular internalization.
Shi’s group used folic acid as a targeting moiety for SPIONs for targeted
MRI of tumors. SPIONs were synthesized by co-precipitation method. A layer-bylayer self-assembly method was used to functionalize SPIONs with dendrimer
decorated folic acid. The results showed an enhanced in cellular uptake of the
SPIONs containing folic acid in tumor cells overexpressed folate receptors. MR
images showed a higher increase in the contrast when incubating the folatedecorated SPIONs with human epithelial carcinoma cell line (KB cells) indicating
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the targeting effect of the conjugates [71]. In a recent study done by Akal et al.,
SPIONs were functionalized with APTES ((3-Aminopropyl) triethoxysilane),
polyethylene glycol (PEG) and folic acid for the targeted delivery of Quercetin for
brain cancer. Prussian blue staining and fluorescence spectroscopy studies
showed a higher cellular uptake of the SPIONs containing folic acid. The Quercetin
loaded folate-decorated SPIONs showed a higher anticancer activity when tested
on U87 cell line (brain adenocarcinoma cells, which have high expression of folate
receptors), as compared to L929 cell line (fibroblast cells, which are folic acid
receptors negative cells). The results are in accordance with previous studies,
suggesting SPIONs modified with appropriate targeting ligands could result in a
better accumulation in tumor cells which possess complementary receptor binding
domains.

1.5. SPIONs coated FA-PAMAM as a multifunctional agent for
cancer imaging and therapy
In this study, SPIONs were synthesized by coprecipitation method, followed
by surface coating and fabrication of PAMAM-decorated FA. The magnetic
nanocarriers were used to encapsulate a poorly aqueous soluble but highly potent
anticancer drug 3,4-difluorobenzylidene diferuloylmethane (CDF), a synthetic
analog of a potent flavonoid anticancer compound diferuloylmethane. In our
previous studies, CDF has shown a high anticancer activity when tested on
pancreatic, cervical, ovarian and lung cancer cells [7–9,72]. The improvement in
anticancer properties of CDF was attributed to a 16-fold increased half-life, a
higher stability, and bioavailability as compared to its natural counterpart. CDF has
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shown to be able to inhibit the growth of cancer cells through down-regulation of
multiple miRNAs, up-regulation of phosphatase and tensin homolog (PTEN), and
attenuation of histone methyltransferase EZH2 [10–12]. The theranostic capability
for cancer imaging and therapy of the magnetic nanocarriers encapsulated CDF
was examined by in vitro biological studies, cellular uptake, and T2 relaxation
studies. The results demonstrated that the synthesized magnetic nanocarriers
could be promising carriers in active targeting cancer imaging and therapy (Fig. 1).

Figure 1. The pictorial representation of accumulation of targeted formulation
(SPIONs@FA-PAMAM-CDF) at the tumor site by EPR-effect, followed by folate
receptor mediated endocytosis of the formulation due to the specific binding of FA
to folate receptors overexpressed on cancer cells.
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CHAPTER 2 EXPERIMENTAL DESIGN
2.1. Materials
2.1.1. Reagents
CDF was synthesized as described earlier [7,13]. Fourth generation (4.0G)
PAMAM dendrimer, ferrous chloride (FeCl 2.4H2O), ferric chloride (FeCl 3.6H2O), N(3-(dimethylamino) propyl)-N-ethylcarbodiimide hydrochloride (EDC), and 3-[4,5
dimethylthiazol-2-yl]-2,5diphenyltetrazolium bromide (MTT) was purchased from
Sigma-Aldrich (St. Louis, MO). FA was purchased from Fisher Scientific. Guava
Nexin Reagent for cell apoptosis kit was purchased from EMD Millipore. All other
chemicals were of reagent grade and used without any modification.

2.1.2. Cell lines
Human cervical cancer cells (HeLa cells) and human ovarian carcinoma
cells (SKOV3 cells) were used in this study due to their high expression of folate
receptors [73–76]. HeLa cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM; Fisher Scientific, Waltham MA) with 10% fetal bovine serum
(FBS) and streptomycin sulfate (10mg/L). SKOV3 cells were cultured in Roswell
Park Memorial Institute (RPMI) 1640 Medium (Thermo Fisher Scientific, USA) with
10% FBS and streptomycin sulfate (10mg/L). All cell lines were incubated at 37oC
in a 5% CO2 air humidified atmosphere.
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2.2. Superparamagnetic iron oxide nanoparticles (SPIONs)
synthesis
Superparamagnetic iron oxide nanoparticles (SPIONs) were synthesized
using co-precipitation method [77]. Prior to the synthesis, 0.5 M NaOH solution in
deionized water (DIW) was prepared in a three-neck 500 ml round bottom flask
(RBF) and degassed by bubbling N2 while stirring at room temperature RT) for 30
min, followed by degas under vacuum while stirring at RT for another 30 min, then
was heated to 40oC. Then, ferric chloride FeCl 3.H2O (6.56 g, 0.024 mol) and
ferrous chloride FeCl 2.4H2O (2.48 g, 0.012 mol) were dissolved in 25 ml of
degassed 0.4 M HCl solution in DIW and then added to the RBF through a septum.
The RBF was heated at 80oC under strong stirring for 1 h. SPIONs were
precipitated using a strong neodymium N52 magnet and then decant the reaction
mixture. The SPIONs were washed 5 times by dispersing them back in EtOH (300
ml) with probe sonication for 10 min, followed by magnet precipitation and decant
the liquid. A dry powder of SPIONs was obtained by drying under vacuum on a
rotary evaporator. The product was characterized by Fourier Transform Infrared
Spectroscopy (FTIR). Hydrodynamic size and zeta potential were characterized by
dynamic light scattering using Beckman Coulter Delsa Nano.

2.3. FA-PAMAM decorated SPIONs fabrication
FA was conjugated to 4th generation PAMAM dendrimers through
carbodiimide coupling chemistry according to our previously reported method [72].
Prior to the FA-PAMAM conjugation, the surface of SPIONs was modified to create
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the activated carboxyl groups (Fig 2). The fabrication process includes three main
steps: amine functionalization, carboxylation, and FA-PAMAM conjugation.

Figure 2. SPIONs
fabrication process.

decorated

FA-PAMAM

(SPIONs@FA-PAMAM)

2.3.1. Amine functionalized SPIONs (SPIONs@APTS)
Synthesized

SPIONs

were

functionalized

by

(3-aminopropyl)

trimethoxysilane (APTS) to have peripheral amino groups [78–80]. Briefly, 1g of
SPIONs were dispersed in 300 ml EtOH with probe sonication for 1 h. Then 6 ml
of APTS was added to the EtOH solution. The solution was sonicated for another
1 h. The resulting product SPIONs@APTS were precipitated using a strong
neodymium N52 magnet and then the reaction mixture was decanted. The product
was washed 3 times by dispersing in 300 ml EtOH with probe sonication, followed
by magnet decantation. SPIONs@APTS were dried under vacuum on a rotary
evaporator. Energy dispersive X-ray spectroscopy (EDS) and FTIR spectroscopy
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were used to characterized the product. Size and zeta potential were measured by
Beckman Coulter Delsa Nano instrument.

2.3.2. Carboxylation of amine functionalized SPIONs (SPIONs@COOH)
Succinic anhydride was used to carboxylate the amine groups of
SPIONs@APTS according to previously reported study [81]. Briefly, 100 mg of
SPIONs@APTS were dispersed in 150 ml EtOH using probe sonication. Succinic
anhydride (500 mg) was added to 150 ml of DMSO under vigorous stirring and
then added to the SPIONs@APTS in EtOH solution. The reaction was stirred at
RT for 24 h. The resulting product SPIONs@COOH were precipitated using a
strong neodymium N52 magnet, followed by the decantation of the supernatant.
The product SPIONs@COOH were washed 3 times by dispersing in 300 ml EtOH
using probe sonication, followed by decantation, and were dried under vacuum on
a rotary evaporator. The product was confirmed by FTIR spectroscopy, size, and
zeta potential measurements.

2.3.3. Activation of SPIONs@COOH and fabrication of FA-PAMAM and
SPIONs@COOH conjugate
Carboxyl groups of SPIONs@COOH were activated using carbodiimide
reaction. In brief, 50 mg of SPIONs@COOH were dispersed in 100 ml DMSO using
probe sonication for 1 h. Then, 490 mg EDC and 735 mg NHS were added to the
solution. The reaction was left for 24 h under vigorous stirring. Activated
SPIONs@COOH were conjugated with 100 mg PAMAM or 100 mg FA-PAMAM
(dissolved in DMSO) to have SPIONs@PAMAM or SPIONs@FA-PAMAM. The
final products SPIONs@PAMAM and SPIONs@FA-PAMAM were purified by
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precipitation by a strong neodymium N52 magnet, followed by decantation of the
supernatant. The products were washed 3 times by dispersing in 300 ml EtOH and
followed by magnet decantation. The products were characterized by size and zeta
potential measurements.
To quantify the amount of dendrimers conjugated to SPIONs, PAMAM
dendrimers, and FA-PAMAM conjugates were labeled with Rhodamine B
isothiocyanate according to previously reported method [82]. In short, PAMAM or
FA-PAMAM conjugates were dispersed in 50 ml EtOH. Rhodamine B
isothiocyanate was added to the EtOH dispersion. The amount of Rhodamine B
isothiocyanate was calculated to have the ratio of Rhodamine B isothiocyanate to
PAMAM or FA-PAMAM of 3:1. The reaction was stirred at RT for 1h, and followed
by dialysis in 5L of DIW for 3 times with the molecular weight cut-off 3.5 kDa.
Lyophilization was performed at the end of the dialysis to have the dry powder of
Rhodamine B label PAMAM (RhoB-PAMAM) and Rhodamine B labeled FAPAMAM (RhoB-FA-PAMAM). Fluorescence spectroscopy was employed to
measure

the

fluorescence

of

the

Rhodamine

B

labeled

formulations

(SPIONs@RhoB-PAMAM and SPIONs@RhoB-FA-PAMAM). The amounts of
PAMAM and FA-PAMAM conjugated to SPIONs were calculated based on the
linear equation of Rhodamine B fluorescence and Rho B-PAMAM or Rho B-FAPAMAM concentrations.

2.3.4. Transmission electron microscopic analysis
The size of the synthesize SPIONs and the fabricated product
SPIONs@PAMAM and SPIONs@FA-PAMAM were studied using transmission
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electron microscopy. Samples were prepared according to a previous method [72].
Briefly, 4 µL of each sample (dispersion of 2 mg powder of the sample in 5 ml of
DIW) was applied to a Formvar-coated, carbon-stabilized copper grid (400 mesh).
The copper grid was air-dried and negatively stained with 5% aqueous uranyl
acetate, and was allowed to dry. Samples were analyzed by JEOL Transmission
electron microscope equipped with LaB6 filament gun (JEM 2010, Tokyo, Japan)
at an accelerating voltage of 200 kV.

2.4. CDF encapsulation
Anticancer drug CDF was encapsulated in SPIONs@PAMAM and
SPIONs@FA-PAMAM separately using equilibrium dialysis method as described
earlier [72,83]. Briefly, CDF and SPIONs formulations were calculated to have CDF
and dendrimer (PAMAM or FA-PAMAM) at the molar ratio of 50:1. Both CDF and
SPIONs@PAMAM or SPIONs@FA-PAMAM were dissolved in the mixture of
DMSO and phosphate buffered saline (PBS) pH 7.4 (ratio 4:6). The mixed solution
was stirred in the dark at a low speed of 50 rpm for 72h at RT. The CDF
encapsulated SPIONs@PAMAM-CDF and SPIONs@FA-PAMAM-CDF were
precipitated using a strong neodymium N52 magnet. The supernatant was used
for indirect drug loading method. After decantation, the formulations were washed
by dispersing in 100 ml EtOH by vortexing, followed by magnet decantation. Dry
products were obtained by drying under vacuum on a rotary evaporator.
The remaining CDF in the supernatant after drug loading was determined
by High-performance liquid chromatography (HPLC) method using a C18 column
with photodiode array detector (PDA) at 447 nm.

For the remaining CDF
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concentration determination, a standard curve of CDF was made by dissolving
known amounts of CDF in DMSO and its successive dilutions in the mobile phase,
followed by HPLC analysis at the absorbance of 447 nm. A known amount of the
supernatant containing unloaded CDF was diluted in DMSO, followed by further
dilution in the mobile phase and HPLC analysis at the absorbance of 447 nm. The
amount of remaining CDF was calculated based on the CDF standard curve, and
the percentage of CDF loaded in the formulations were calculated based on the
subtraction of the initial amount of CDF and the remaining amount of CDF.

2.5. Fluorescence microscopy study
Fluorescence microscopic study was performed in SKOV3 cells to compare
the targeting ability of SPIONs@FA-PAMAM and SPIONs@PAMAM. In brief,
SKOV3 cells were seeded in a four-well chamber slide (5 x 104 cells in each well)
and incubated at 37oC in a 5% CO 2 air humidified atmosphere for 24 h. The
medium was removed and Rhodamine B labeled formulations (SPIONs@PAMAMRho and SPIONs@FA-PAMAM-Rho) were added and incubated for 6 h. The
formulation containing medium was removed, and cells were washed for 3 times
with cold PBS (pH 7.4), and fixed with 3% formaldehyde in the PBS pH 7.4 at RT
for 10 min. Samples were analyzed qualitatively using a fluorescent microscope
(Leica, Germany) [84].
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2.6. T2 relaxivity and in vitro relaxometry and imaging studies
2.6.1. T2 relaxivity studies of SPIONs, SPIONs@PAMAM, and
SPIONs@FA-PAMAM
T2 relaxometry was performed using a 7.0 T Bruker ClinScan system. The
instrumental parameters wecre set as follows: a 7.0 T magnetic field strength, pixel
spacing at 0.297/0.297, repetition time 2000 ms, echo time 11 ms, and slice
thickness of 2 mm. Synthesized SPIONs and their modification SPIONs@PAMAM
and SPIONs@FA-PAMAM were analyzed at different iron concentrations 10, 20,
40, 60, 80, and 100 μg/ml. The T 2 relaxivity was calculated from the linear slope of
the inverse T2 (1/T2) relaxation time according to the iron concentration.

2.6.2. In vitro MR relaxometry and imaging
5 x 105 HeLa and SKOV3 cells were incubated with both the non-targeted
formulation SPIONs@PAMAM and the targeted formulation SPIONs@FAPAMAM at iron concentrations of 10,20,40, and 80 μg/ml for 30 min at 4 oC
according to the previously reported method [59]. In short, 5 x 105 HeLa and
SKOV3 cells were trypsinized and suspended in cold PBS (in an ice bath) and
incubated with the formulations. After 30 min incubation, cells were centrifuged
down at 800 rpm for 3 min to form a pellet. Cells were washed 3 times with cold
PBS to remove free particles. Final pellets were resuspended in cold PBS and
used for MR imaging. A phantom was constructed consisting of all of the sample
vials. The instrumental parameters were set a 7.0 T magnetic field strength, pixel
spacing at 0.297/0.297, repetition time 2000 ms, echo time 11 ms, and slice
thickness of 2 mm.
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2.7. In vitro cytotoxicity study
The in vitro cytotoxicity of free CDF, SPIONs@PAMAM-CDF, and
SPIONs@FA-PAMAM-CDF formulations were evaluated by MTT assay on HeLa
and SKOV3 cell lines. In brief, HeLa and SKOV3 cells were seeded in 96 wellplates with an average of 3000 cells in each well. After 24 h incubation at 37oC in
a 5% CO2 air humidified atmosphere, cells were treated with various formulations
with a concentration range from 0.25 μM to 5 μM. Treated cells were incubated for
72 h at 37oC followed by addition of MTT solution (1mg/ ml) and further incubation
at 37oC for 3h. Then, the media was replaced by DMSO (100 μl in each well). The
absorbance was measured at 590 nm using a high-performance multi-mode plate
reader Synergy 2 (BioTek). The percentage of viable cells was determined by
comparing the absorbance with appropriate controls [7,13].

2.8. Folate receptor blocking assay
The folate receptor blocking assay was performed to understand the
mechanism by which the targeting SPIONs@FA-PAMAM-CDF internalize HeLa
and SKOV3 cells via folate receptor mediated endocytosis. This assay is based on
the principle of the initial blockade of folate receptors of HeLa and SKOV3 by
adding an excess amount of free FA (1 mM) [72], followed by treatment with
formulations (CDF, SPIONs@PAMAM-CDF, and SPIONs@FA-PAMAM-CDF).
The cell viability of HeLa and SKOV3 were determined by MTT assay after 72 h
incubation at 37oC. This assay is performed according to the previously reported
protocol [85]. In short, HeLa and SKOV3 cells were seeded in 96 well-plates for 24
h, followed by addition of 100 μl of 1mM FA in each well and incubation at 37 oC
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for 3 h. Then, cells were washed twice with PBS (pH 7.4), followed by media and
addition of formulations. After 72 h incubation at 37 oC, MTT assay was performed
to determine the cell viability as stated in the previous section.

2.9. Apoptosis assay by flow cytometry
Apoptosis assay was performed on HeLa cell line according to our previous
study [72]. In brief, HeLa cells were cultured in 6-well plates at 5x104 cells in each
well and incubated for 24 h at 37 oC under 5% CO2, followed the treatment of plain
CDF,

SPIONs@PAMAM-CDF,

and

SPIONs@FA-PAMAM-CDF

to induce

apoptosis. The concentration of CDF, SPIONs@PAMAM-CDF and SPIONs@FAPAMAM-CDF were chosen based on the IC50 value of CDF on HeLa cells from the
in vitro cytotoxicity assay. After 72h incubation, cells were collected and the sample
was prepared according to the protocol for Guava Nexin Annexin V assay (EMD
Millipore, USA). In short, media and trypsinized treated cells were collected in 15
ml tubes and centrifuged at 300 x g for 7 min. Cell pellets were dispersed in PBS
pH 7.4 with 1% FBS to have the number of cells in the range of 2 x 10 5 – 1 x 106
cells/mL. Then 100 μL of cell dispersion of each sample was added 100 μL of the
Guava Nexin Reagent and was incubated for 20 min at RT in the dark. The
samples were analyzed by Guava Easycyte flow cytometer (EMD Millipore, USA).

2.10. Western blot
Western blot analysis was performed to determine the level expression of
Phosphatase and tensin homolog PTEN and Nuclear factor kappa B (NF-κB) in
HeLa cell line using reported method [86]. Briefly, HeLa cells were treated with
different formulations as well as free CDF and lysed. The protein concentration
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was determined by the Bio-Rad Protein Assay (Bio-Rad kit). Lysates were
electrophoresed by SDS-PAGE and the proteins were transferred onto the
nitrocellulose blotting membrane, followed by blocking with 5% BSA in TBST buffer
at RT for 1h. Primary PTEN or NF-κB antibodies were added and incubated
overnight at 4oC, subsequently washed and incubated with compatible secondary
antibodies.

The

protein

bands

were

visualized

by

incubation

with

chemiluminescent substrate (Thermos scientific) at room temperature for 2 min,
followed by chemiluminescent detection using a digital imaging system
ImageQuant LAS 4000 (GE Healthcare Bio-Sciences AB, Sweden).
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CHAPTER 3 RESULTS
A vast majority of cancer cells are known to have a high expression of folate
receptors, while normal tissues and organs have very limited expression of folate
receptors [87]. Many studies have shown an enhance in anticancer activity
employing folic acid decorated nanocarriers in different cancer types such as
ovarian, lung, cervical, breast, kidney, colorectal, epithelial and brain cancers
[85,88–90]. CDF has been shown a high anticancer activity against various types
of cancers as well as overcome drug resistance [11,86]. However, extremely low
aqueous solubility of CDF makes its systemic administration problematic. Our
previous study suggested that PAMAM dendrimer conjugated with folic acid could
improve the aqueous solubility of CDF dramatically and gave the active targeting
with an enhanced anticancer activity due to the folate receptor mediated
endocytosis [72]. In addition, many studies reported the potential usage in
biomedical imaging of PAMAM dendrimers when fabricated with magnetic iron
oxide nanoparticles [59,78,91–93]. Based on these information, the goal of this
present work was to design a theranostic nanoparticles consisting of FA-PAMAM
conjugate as the outer shell and iron oxide nanoparticles as the inner core loaded
with CDF which could be used in both cancer imaging and therapy for multiple
cancers.

3.1. SPIONs synthesis and characterization
The magnetic iron oxide nanoparticles SPIONs were synthesized by
controlled co-precipitation of Fe2+ and Fe3+ ions according to previously reported
method [77,94,95]. The synthesized SPIONs were confirmed by FTIR
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spectroscopy. The presence of Fe3O4 core was identified by the strong stretching
absorption band between 408 and 673 cm-1 corresponding to the Fe-O bond of the
particles (Fig. 3a) [78]. Dynamic light scattering technique measurement showed
a hydrodynamic size of 78.8 nm (PDI 0.177) and a zeta potential at – 59.73 mV
(Fig. 3d).

Figure 3. (a) FTIR spectra of SPIONs, SPIONs@APTS, and
SPIONs@COOH; (b) Energy dispersive X-ray spectroscopy (EDS) analysis of
SPIONs@APTS; (c) Hydrodynamic size of the fabricated nanoparticles
SPIONs@PAMAM and SPIONs@FA-PAMAM; and (d) Zeta potential
measurement of each step of the fabrication process are shown.
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3.2.

FA-PAMAM

decorated

SPIONs

fabrication

and

characterization
3.2.1. Amine functionalized SPIONs (SPIONs@APTS)
The sonication time was optimized according to previous reported method
[78]. Sonication of the synthesized SPIONs before modification with APTS
improved the magnetic properties and size distribution of the particles. After
aminosilane modification of the SPIONs, the achieved product SPIONs@APTS
could be dispersed back in DIW to form a stable dispersion with a hydrodynamic
size of 95.9 nm (PDI 0.113). SPIONs@APTS showed a zeta potential of 56.94 mV
confirming the presence of the positively charged amine groups of APTS (Fig 3d).
Energy-dispersive X-ray spectroscopy (EDX) spectrum showed the unique peak
of Si further confirmed the successful coating of the aminosilane APTS on the
surface of SPIONs (Fig 3b). FTIR spectrum confirmed the presence of APTS on
the surface of SPIONs with the characteristic peaks of C-H at 2888, 2979 cm-1, SiC at 1330 cm-1, Si-O at 1049 cm-1, and Fe-O at 574 cm-1 (Fig. 3a).

3.2.2. Carboxylation of amine functionalized SPIONs (SPIONs@COOH)
The carboxylation of primary amine groups on the surface of
SPIONs@APTS was confirmed by the change in zeta potential from a positive
charge of 56.94 mV (of the amine groups) to a negative charge of -63.22 mV (of
the carboxyl groups) (Fig 3d). FTIR spectrum of SPIONs@COOH showed the
characteristic peaks of C-H bond at 2981 cm-1 and 2862 cm-1, Si-O bond at
1045cm-1, Fe-O bond at 571 cm-1, and the C=O stretching at 1700 cm-1 (Fig. 3a).
SPIONs@COOH had a hydrodynamic size of 96.2 nm (PDI 0.246).
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3.2.3. Activation of SPIONs@COOH and fabrication of FA-PAMAM and
SPIONs@COOH conjugate
Zeta potential was used to confirmed the conjugation of PAMAM and FAPAMAM to the activated SPIONs@COOH. Before conjugation, SPIONs@COOH
had the zeta potential of -63.22 mV. After the conjugation, the zeta potential values
were changed to 48.79 mV and 9.97 mV in case of SPIONs@PAMAM and
SPIONs@FA-PAMAM, respectively (Fig. 3d). Dynamic light scattering showed an
average size of 110.1 nm (PDI 0.125) and 159.4 nm (PDI 0.127) of
SPIONs@PAMAM

and

SPIONs@FA-PAMAM,

respectively

(Fig

3c).

Fluorescence spectroscopy measurement showed an average of 20.37% (wt/wt)
of PAMAM in SPIONs@PAMAM, and 27.61% (wt/wt) of FA-PAMAM conjugates in
SPIONs@FA-PAMAM structure.

3.2.4. Transmission electron microscopic analysis
To further determine the size of the nanoformulations, electron microscopic
analysis of the synthesized SPIONs, and the carrier SPIONs@PAMAM and
SPIONs@FA-PAMAM was performed. TEM images showed that the morphology
of the fabricated SPIONs was remained the same as the unmodified SPIONs. TEM
data showed that the inner SPIONs core had the average size of 11 nm confirming
the nano-metric size of the formulations (Fig. 4).
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Figure 4. Transmission electron microscopic images of SPIONs,
SPIONs@PAMAM and SPIONs@FA-PAMAM show the morphology of the
fabricated nanoparticles.

3.3. CDF drug loading in nanoparticles
The CDF drug loading was studied based on the indirect method. The
remaining of CDF in the supernatant after drug loading was measured by HPLC
method. A calibration curve of CDF was developed from 10 μg/ml to 250 μg/ml
with the R2 value of 0.99. The HPLC method was validated for its accuracy and
precision and was used to determine the CDF concentration. The loading of CDF
in SPIONs@PAMAM and SPIONs@FA-PAMAM was 12.37% (wt/wt) and 9.81%
(wt/wt), respectively.

3.4. Fluorescence microscopy study
SKOV3 cells were selected for in vitro fluorescence microscopic study
based on the results of in vitro cytotoxicity assay and receptor blocking assay to
compare the level of cellular internalization of the non-targeted formulation
SPIONs@PAMAM-CDF and the targeted formulation SPIONs@FA-PAMAM-CDF.
In this cell uptake studies, SKOV3 cells were incubated with Rhodamine B (having
red fluorescence) labeled nanoformulations and analyzed after 6 hours of
incubation at 37oC in the dark. As shown in figure 5, SKOV3 cells treated with both
of the non-targeted and the targeted formulations showed apparent fluorescence.
As compared to the non-targeted formulation, there was a significantly higher
fluorescence in cells treated with targeted formulations.
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Figure 5. Fluorescence microscopic images (40X) of SKOV3 cells
incubated with nuclear stain Hoechst (blue fluorescence) and Rhodamine B (red
fluorescence) labeled non-targeted SPIONs@PAMAM and targeted formulations
SPIONs@FA-PAMAM at 6 h are shown.

3.5. T2 relaxivity and in vitro relaxometry and imaging studies
3.5.1. T2 relaxivity studies of SPIONs, SPIONs@PAMAM and
SPIONs@FA-PAMAM
T2 relaxivity studies were performed to examine the magnetic behavior of
the

synthesized

SPIONs

and

the

nano-carrier

SPIONs@PAMAM

and

SPIONs@FA-PAMAM in their biomedical application in MR imaging. The potential
of the fabricated magnetic nanoparticles SPIONs@PAMAM and SPIONs@FAPAMAM to be used as T2-based contrast agent for MR imaging was evaluated
using the measured transverse relaxation time (T 2) of SPIONs@PAMAM and
SPIONs@FA-PAMAM as compared to SPIONs. The T2 values were used to
calculate the transverse relaxivity rate (r2) per μg/ml of iron, which showed the
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efficiency of the fabricated nanoparticles as a MR contrast agent. From figure 6a,
there was a significant decrease in the signal intensity of the T 2-weighted MR
images with the increase of iron concentration in both of the non-targeted
SPIONs@PAMAM and the targeted SPIONs@FA-PAMAM nanoparticles as
compared to the control PBS. Pseudo-color MR images showed a decrease in
signal intensity for the fabricated nanoparticles from red (high intensity) to purple
(low intensity). The T2 relaxation rate (1/T2) increased linearly with the iron
concentration (μg/ml) in both cases of the non-targeted SPIONs@PAMAM and the
targeted SPIONs@FA-PAMAM nanoparticles. The slope values (r 2) were
calculated to be 1.92 (μg/ml)-1s-1 and 1.81(μg/ml)-1s-1 in case of SPIONs@PAMAM
and SPIONs@FA-PAMAM, respectively. Unmodified SPIONs had the slope value
(r2) of 2.01 (μg/ml)-1s-1. The results suggested that both of the non-targeted
nanoparticle SPIONs@PAMAM and the targeted nanoparticle SPIONs@FAPAMAM could be used as T2-shortening agents.

3.5.2. In vitro MR relaxometry and imaging studies
In vitro MR relaxometry and Imaging studies were performed to examine
the effect of the targeting ability of folate-based nanoparticle SPIONs@FAPAMAM in MR imaging. To study the effect of SPIONs@PAMAM and
SPIONs@FA-PAMAM on SKOV3 and HeLa cells, we measured the T 2 of SKOV3
and HeLa cells after incubation with different concentration of SPIONs@PAMAM
and SPIONs@FA-PAMAM for 30 min. There was a significant decrease in signal
intensity in SKOV3 and HeLa cells when incubated with the targeted nanoparticle
SPIONs@FA-PAMAM. In contrast, non-targeted nanoparticle SPIONs@PAMAM
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showed a very little decrease in the signal intensity in both SKOV3 and HeLa cells.
In the T2-weighted MR images, targeted formulation SPIONs@FA-PAMAM at the
iron concentration of 80 μg/ml decreased the MR signal intensity to 45.6% in
SKOV3 and 28% in HeLa, as compared to 100% of PBS control. However, nontargeted nanoparticle SPIONs@PAMAM at the iron concentration of 80 μg/ml
showed a lower decrease in MR signal intensity with 87% in SKOV3 and in 71.4%
HeLa, as compared to 100% of control PBS (Fig 6b).

Figure 6. (a) T2-weighted MR images of the aqueous dispersion of
SPIONs@PAMAM and SPIONs@FA-PAMAM with the T2 relaxation rate (1/T2) as
a function of iron concentration indicating the ability of the fabricated nanoparticles
to enhance the contrast in MR images; (b) MR images of SKOV3 and HeLa cell
pellets after 30 min incubation with the non-targeted SPIONs@PAMAM and the
targeted SPIONs@FA-PAMAM nanoparticles (with the color change from red to
purple indicating the gradual decrease of MR signal intensity). The percentage of
signal intensity compared to cells in PBS was plotted as a function of iron
concentration indicating the faster internalization with a higher decrease in MR
signal intensity of the targeted SPIONs@FA-PAMAM.
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3.6. In vitro cytotoxicity study
In vitro cytotoxicity of the CDF loaded nanoformulations was examined in 2
cell lines [SKOV3 (human ovarian carcinoma cell line), HeLa cells (human cervical
cancer cells)] with a broad range of CDF concentrations (0.25 µM - 5 µM). Plain
targeted carrier (SPIONs@FA-PAMAM) showed negligible cytotoxicity with cell
viability more than 90% confirming the safety of the targeted carrier. The
anticancer

activity

of

the

nanoformulations

(non-targeted

formulation

SPIONs@PAMAM-CDF and targeted formulation SPIONs@FA-PAMAM-CDF)
was studied and compared with free drug CDF. The results showed a dosedependent cell killing for both SPIONs@PAMAM-CDF and SPIONs@FA-PAMAMCDF. The outcome of the study revealed an IC50 (half maximal inhibitory
concentration) of 0.45 µM, 0.78 µM, and 1.79 µM for free CDF, SPIONs@FAPAMAM-CDF, and SPIONs@PAMAM-CDF, respectively in SKOV3 cells. The
noticeably lower IC50 of the targeted SPIONs@FA-PAMAM-CDF as compared to
the non-targeted SPIONs@PAMAM-CDF was probably due to the folate receptorspecific targeting of SPIONs@FA-PAMAM-CDF. The same pattern was also
observed in HeLa cells with the IC50 of 0.66 µM, 0.87 µM, and 1.98 µM for free
CDF, SPIONs@FA-PAMAM-CDF, and SPIONs@PAMAM-CDF, respectively (Fig.
7a).
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Figure 7. (a) In vitro cytotoxicity assay showing percentage of cell viability
observed at 72 h after treating SKOV3 and HeLa cells with various formulations
are shown (n=8); (b) MTT assay observed at 72 h after folate receptor blocking
and treating of SKOV3 and HeLa cells with SPIONs@PAMAM-CDF and
SPIONs@FA-PAMAM-CDF are shown (n=8); (c) Induction of apoptosis in HeLa
cells when treated with CDF, SPIONs@PAMAM-CDF, and SPIONs@FA-PAMAMCDF as evaluated by Annexin V/7-AAD dual staining. An increased percentage of
the apoptotic cell population was noted when cells were treated with targeted
formulation (SPIONs@FA-PAMAM-CDF) as compared to the non-targeted
formulation (SPIONs@PAMAM-CDF), suggesting the better killing activity of the
targeted formulation SPIONs@FA-PAMAM-CDF.
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3.7. Folate receptor blocking assay
Folate receptor blocking assay was performed to examine the fate of the
folate-based targeting formulation. SKOV3 and HeLa cells with high expression of
folate receptors were treated with an excess amount of FA (1 mM) to overwhelm
the folate receptor binding domains on the cell membrane, followed by the
treatment with the nanoformulations [73–76,96]. In vitro cytotoxicity MTT assay
was used to determine the change in the cell viability in SKOV3 and HeLa treated
with the formulations after blocking the folate receptors. It was observed that
before blockade of folate receptors, the IC 50 values on SKOV3 were 0.80 µM and
1.81 µM for the targeted SPIONs@FA-PAMAM-CDF and the non-targeted
SPIONs@PAMAM-CDF, respectively. After the blockade of folate receptors, the
IC50 value of the targeted SPIONs@FA-PAMAM-CDF was increased to 1.36 µM.
However, there was not a significant change in the IC 50 of the non-targeted
SPIONs@PAMAM-CDF (1.82 µM). The same outcome was observed in HeLa
cells with the IC50 of 0.85 µM and 2 µM for SPIONs@FA-PAMAM-CDF and
SPIONs@PAMAM-CDF, respectively before the folate receptor blockade. After
blocking folate receptors, the IC50 values were found to be 1.26 µM and 1.94 µM
for SPIONs@FA-PAMAM-CDF and SPIONs@PAMAM-CDF, respectively. The
results suggested a decrease in anticancer activity of the targeted formulation
SPIONs@FA-PAMAM-CDF in SKOV3 cells when folate receptors are blocked
(Fig. 7b).
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3.8. Apoptosis assay
HeLa cells were selected for this apoptosis assay. Apoptosis induction in
HeLa cells of free CDF and the CDF loaded formulations was determined by flow
cytometry with Annexin V/7-AAD dual staining. The percentage of Annexin V-/7AAD - (R5), Annexin V+/7-AAD - (R6) and Annexin V-/7-AAD + (R4) and Annexin V/7-AAD + (R3) were used to determine the number of live cells, early apoptotic, late
apoptotic and necrotic cells. Apoptosis assay revealed a higher percentage of
apoptotic and necrotic HeLa cells (34.2 ± 3.2 %) after treatment with the targeted
formulation SPIONs@FA-PAMAM-CDF. Non-targeted formulation showed a lower
number of apoptotic and necrotic cells at 20.5 ± 2.7 % of the cell population. The
results suggested a higher apoptosis induction ability of the targeted formulation
SPIONs@FA-PAMAM-CDF as compared to the non-targeted formulation
SPIONs@PAMAM-CDF (Fig. 7c). The results were consistent with higher
anticancer activity of the targeted formulation SPIONs@FA-PAMAM-CDF in in
vitro cytotoxicity assay using MTT with higher cellular uptake in fluorescence
microscopic studies and in vitro relaxometry and imaging studies.

3.9. Western blot
Western blot was performed to examine the level expression of PTEN and
NF-κB in HeLa cells after treatment with the nanoformulations. In case of NF-κB,
control HeLa cells without treatment showed a higher expression of NF-κB as
compared to HeLa cells treated with plain CDF and the nanoformulations.
Targeted formulation SPIONs@FA-PAMAM-CDF showed a slightly better
downregulation of NF-κB (76.4 ± 4.6 % as of control) as compared to the non-
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targeted formulation SPIONs@PAMAM-CDF (83.6 ± 8.2 % as of control). In case
of PTEN expression, the control HeLa cells without treatment showed a
significantly low expression of PTEN. However, after treatment with plain CDF and
nanoformulations, PTEN expression was elevated. Noticeably, in comparison to
control, HeLa cells treated with the targeted formulation SPIONs@FA-PAMAMCDF showed the highest upregulation of PTEN expression (319.9 ± 27.1 %) as
compared to free CDF (158.9 ± 13.5 %) and the non-targeted formulation
SPIONs@PAMAM-CDF (214.2 ± 10.9%) (Fig. 8).

Figure 8. Western blot analysis showing PTEN and NF-κB expression in HeLa
cells in control without treatment (CTL), and cells treated with CDF, targeted
formulation SPIONs@FA-PAMAM-CDF (T) and non-targeted formulation
SPIONs@PAMAM-CDF (NT), (GAPDH expression was used as the protein
loading control).
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CHAPTER 4 DISCUSSION
The bleak prognosis for patients diagnosed with metastatic cancer along
with the high costs of treating cancer in its advanced stages are urging for a better
predictive and preventative method [97]. With the advantages of noninvasive MR
imaging with superb spatial resolution, targeting MRI contrast agents are believed
to be critical tools which can fully benefit from this new technique [98,99]. The
targeting ability of MRI contrast agents depends strongly on their ability to carry
specific molecular markers for tumor recognition. As a result, the tumor can be
visualized and diagnosed earlier accurately leading to an effective treatment, and
ultimately improving patient survival [37,98]. In this regards, PAMAM dendrimers
with the ability to conjugate targeting ligands through numerous peripheral reactive
amine groups have been studied recently for surface modification of iron oxide
nanoparticles for targeting MRI [78,100,101]. In terms of targeting ligands, folic
acid recently has received considerable attention as a targeting ligand to target
folate receptors overexpressed on numerous types of tumors [89,90,96,102–106].
PAMAM dendrimers conjugated folic acid can take advantage of the favorable
binding of targeting ligand folic acid to folate receptors on tumor cells to enhance
the cellular uptake via folate receptor mediated endocytosis. Many studies have
shown that iron oxide nanoparticles decorated with folate-based PAMMA
dendrimer could achieve MRI targeting with higher cellular internalization in cancer
cells with a higher contrast in T2-weighted MR images [59,71,78]. However, in most
of the studies, the ability of PAMAM dendrimers in drug delivery was not fully
examined.
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The poor aqueous solubility of several potent anticancer compounds could
be a major issue and deciding factor in realizing its translation potential from the
bench to the bedside. The non-specific distribution of chemotherapeutic agents in
the systemic circulation gives the conventional chemotherapy a low therapeutic
index and severe side effects which cause the treatment to be ineffective and lead
to the recurrence of tumor after initial treatment. Recently, CDF has been shown
to be a very potent anticancer compound with the ability to treat different types of
cancers [12,13,72]. However, low solubility profile of CDF makes its systemic
administration problematic. In this regard, PAMAM dendrimers have revealed
promising potentials. Our earlier reported study suggested that folate-decorated
PAMAM dendrimers could encapsulate CDF in their hydrophobic cavities for
aqueous solubility enhancement and deliver CDF specifically to the tumor site with
minimizing adverse side effects [72]. The aim of this study was to design a
theranostic carrier consisting of iron oxide nanoparticles with folate-based PAMAM
dendrimers for active targeting MR imaging and anticancer drug delivery. As a
result, the targeted nanoparticles SPIONs@FA-PAMAM can enhance the aqueous
solubility of CDF and deliver it specifically to cancer cells with a higher contrast in
T2-weight MR images.
The synthesis of SPIONs was confirmed by FTIR spectrum with the
characteristic peak of Fe-O at 574 cm-1. The synthesized SPIONs could be
dispersed back in DIW or EtOH to form a stable dispersion with a hydrodynamic
size of 78.8 nm (PDI 0.177) and a zeta potential of -59.73 mV. TEM images of
SPIONs showing an average size at 10.5 ± 1 nm further reconfirmed the success
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of the synthesis. Surface modification of SPIONs was confirmed by zeta potential
with a change from an initial zeta potential of -59.73 mV of SPIONs to 56.94 mV
of SPIONs@APTS, and -63.22 mV of SPIONs@COOH (Fig 3d). In EDX analysis
of SPIONs@APTS, the atomic ratio of Fe/Si was shown to be 17.55/1 (Fig. 3b).
The mathematic calculation was used to estimate the number of silanes per gram
particles according to the reported method [77]. From TEM images, synthesized
SPIONs were shown to have an average diameter (r SPIONs) of 5.5 nm; therefore,
the surface area (SASPIONs) of one particle is 380 nm2 (SASPIONs = 4πrSPIONs2). One
silane is known to cover an approximately 0.4 nm2 of the particle’s surface area,
so we have an average of 950 silanes covered the surface of one SPION [77].
With the atomic ratio 17.55/1 of Fe/Si in SPIONs@APTS from EDX analysis, it is
estimated that 950 silanes would cover one particle with an average of 16,672.5
iron atoms. Therefore, 1 g of SPIONs would have an average of 0.099 g of APTS
coating, theoretically.
PAMAM and FA-PAMAM conjugation was confirmed by a change in zeta
potential. After conjugation, SPIONs@PAMAM and SPIONs@FA-PAMAM had a
zeta potential of 48.79 mV and 9.97 mV, respectively (Fig. 3d). FA conjugation
helped the targeted carrier SPIONs@FA-PAMAM reduce the highly positive
charge, which is known to be associated with the toxicity of PAMAM dendrimers
[16]. The morphology of nanoparticles could be affected by several factors
including the fabrication and reaction involved. The shape and size of
nanoparticles could have a high impact on their biodistribution, clearance, and
biocompatibility [107]. TEM images suggested that the morphology of the particles
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remained unchanged after the fabrication. Dynamic light scattering measurement
showed that both of the non-targeted and targeted formulations were in the nanosized range with an average hydrodynamic size of 110.1 nm (PDI 0.125) and 159.4
nm (PDI 0.127) of SPIONs@PAMAM and SPIONs@FA-PAMAM, respectively (Fig
3c). A higher value in hydrodynamic size of SPIONs@FA-PAMAM could be
attributed to the presence of FA resulting in a low positive charge of the particles.
Drug loading studies showed a little higher in CDF encapsulation in SPIONs@FAPAMAM-CDF as compared to SPIONs@PAMAM-CDF. The presence of FA might
be responsible for a higher drug loading with a shielding effect outside the
hydrophobic cavities; thus, a higher amount of CDF was encapsulated inside the
hydrophobic cavities.
Targeting ability of folate-decorated nanoformulations was examined in
fluorescence microscopic study on SKOV3 cell line. SKOV3 cells treated with
Rhodamine B labeled targeted formulation SPIONs@FA-PAMAM-CDF showed a
significantly higher red fluorescence intensity of Rhodamine B dye as compared to
the Rhodamine B labeled non-targeted formulation SPIONs@PAMAM. The
fluorescence microscopic images were taken after only 6 h incubation of SKOV3
cells with the Rhodamine B labeled formulations, which proved the ability of the
targeted formulation to internalize the cells within such a short time frame [Fig 5].
The magnetic behavior of the non-targeted SPIONs@PAMAM and the
targeted SPIONs@FA-PAMAM was examined in the T 2 relaxivity studies to test
their ability to enhance the contrast in MR images [Fig 6]. The T2 relaxation rate
(1/T2) as a function of the iron concentration (from 10 μg/ml to 40 μg/ml) of both of
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the carriers showed that the relaxation rate increases linearly with the iron
concentration with a slope (r2) of 1.92 (μg/ml)-1s-1 and 1.81(μg/ml)-1s-1 for
SPIONs@PAMAM and SPION@FA-PAMAM, respectively. The slightly lower r 2 of
SPIONs@FA-PAMAM may be due to the presence of FA on the periphery of the
particles, which shields water molecules from accessing the surface of SPIONs.
The results suggested that SPIONs@PAMAM and SPIONs@FA-PAMAM could
be used as T2-shortening agents which helped enhance the contrast in the MR
images. To study the effect of the non-targeted SPIONs@PAMAM and the
targeted SPIONs@FA-PAMAM on the MR images of SKOV3 and HeLa cells, T2
of SKOV3 and HeLa cells was measured after 30 min incubation with various
concentrations of SPIONs@PAMAM and SPIONs@FA-PAMAM. The T2 values of
SKOV3 and HeLa cell pellets treated with SPIONs@FA-PAMAM particles
decreased dramatically as a function of iron concentration. In contrast, there was
a small decrease in the T2 values of SKOV3 and HeLa cell pellets treated with the
non-targeted SPIONs@PAMAM particles. In the T 2-weighted MR images (the
color change from red to purple indicates a decrease in MR signal intensity)
observed in SKOV3 and HeLa cells, targeted SPIONs@FA-PAMAM nanoparticles
at 80 μg/ml reduced the signal intensity to 45.6% and 28% of the initial value (PBS
control) in SKOV3 and HeLa cells, respectively; whereas non-targeted
SPIONs@PAMAM nanoparticles at 80 μg/ml reduced the signal intensity to 87%
and 71.4% of the initial value in SKOV3 and HeLa cells, respectively. The results
suggested the targeted nanoparticles SPIONs@FA-PAMAM can specifically
hamper the MR signal intensity through folate receptor mediated endocytosis. The
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results are in accordance with the higher cellular internalization of the targeted
nanoparticles in the fluorescence microscopic studies.
The anticancer activity of the CDF loaded nanoformulations was examined
using the in vitro cytotoxicity assay on SKOV3 and Hela cells. The MTT assay
results showed a high anticancer activity on SKOV3 and HeLa cells with both the
formulations with relatively low IC50. It should be noted that the targeted formulation
SPIONs@FA-PAMAM-CDF showed a higher anticancer activity with lower IC 50 as
compared to the non-targeted formulation SPIONs@PAMAM-CDF when tested at
a concentration range from 0.25 µM to 5 µM. IC50 values of SPIONs@FA-PAMAMCDF were found to be 0.78 µM and 0.87 µM in SKOV3 and HeLa, which were
lower by 2.29 fold and 2.27 fold as compared to the non-targeted
SPIONs@PAMAM-CDF in SKOV3 and HeLa, respectively. The better anticancer
activity of the targeted formulation could be attributed to the targeting effect of FA,
which helped the formulations have a higher degree of cellular internalization via
folate receptor mediated endocytosis. Fourth generation PAMAM dendrimers are
known to be cytotoxic due to the highly positive charge of 64 amino groups on the
periphery. FA conjugation gave the targeted formulation the ability to target folate
receptors overexpressed on cancer cells, and also helped reduce the positive
charge of the nanoconstruct. As a result, SPIONs@FA-PAMAM carrier showed a
relatively safe profile on both SKOV3 and HeLa cells with more than 90% viable
cells at all tested concentrations. The results proved that SPIONs@FA-PAMAM
could be promising carriers for anticancer drug delivery (Fig 7a). The folate
receptor assay was performed to evaluated the fate of the nanoformulations under
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blocking the folate receptors. An increase in IC50 values of the targeted formulation
SPIONs@FA-PAMAM-CDF in SKOV3 and HeLa cells after blocking folate
receptors was observed. In contrast, IC50 values of the non-targeted formulation
SPIONs@PAMAM-CDF did not show a significant change after the blocking of
folate receptors. The results suggested that the higher activity of the targeted
formulation SPIONs@FA-PAMAM-CDF was due to the active targeting ability of
the folate-decorated nanoformulations. However, it should be noted that the IC 50
value of SPIONs@PAMAM-CDF was still higher than SPIONs@FA-PAMAM-CDF
in both SKOV3 and HeLa after the blocking the folate receptors (Fig 7b). The
results suggested that the blocking of folate receptors on SKOV3 and HeLa cells
could decrease the cellular uptake of the targeted formulation to a certain degree,
and when the folate receptors are recycled, the folate receptor mediate
endocytosis pathway was recovered and the targeting ability of SPIONs@FAPAMAM was regained.
As a next step, apoptosis assay and western blot studies were performed
to further examine the targeting ability of the targeted formulation SPIONs@FAPAMAM-CDF in anticancer activity against HeLa cells. It should be noted that free
CDF showed the highest percentage of apoptotic and necrotic cells. This could be
explained by the small molecular weight and the highly lipophilic profile of CDF
which gives CDF a high rate of internalization of passive diffusion. Apoptosis assay
showed a higher percentage of apoptotic and necrotic cells in HeLa after treatment
with the targeted formulation SPIONs@FA-PAMAM-CDF as compared to the nontargeted formulation SPIONs@PAMAM-CDF. A better apoptosis induction ability
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of the targeted formulation SPIONs@FA-PAMAM-CDF could be explained by a
higher cellular uptake of the formulation due to the targeting ability of FA to the
folate receptors overexpressed on HeLa cells [Fig 7c]. The results from apoptosis
assay were in accordance with higher anticancer activity of the targeted
formulation with higher cellular uptake in fluorescence microscopic studies and in
vitro T2 relaxation studies.
Western blot studies were performed on HeLa cells to determine the
expression levels of PTEN and NF-κB after treatment with the formulations. CDF
is known to upregulate PTEN, which is a tumor suppressor gene with a key role in
stem cell self-renewal [86]. PTEN can dephosphorylate phosphatidylinositol 3,4,5triphosphate (PIP3) an antagonize the PI3-K/Akt pathway. It is believed that PTEN
downregulation is a key factor contributing to the development of chemotherapy
resistance and recurrence of various human tumors [108]. PTEN is known to
regulate many cellular processes including growth, adhesion, migration, invasion,
and apoptosis [11,86]. Nuclear factor kappa B (NF-κB) is known to upregulate antiapoptotic genes such as bcl-xL and X-linked inhibitor of apoptosis (XIAP) leading
to induce cell survival. Activation of NF-κB was observed in many types of cancer
and was shown to contribute to apoptosis resistance in cancer cells [109]. In case
of NF-κB expression, control HeLa cells without treatment showed a high
expression of NF-κB. After treatment with CDF and the formulations, NF-κB levels
in HeLa were decreased. Higher downregulation of NF-κB in HeLa cells was found
when cells treated with the targeted formulation SPIONs@FA-PAMAM-CDF
(decreased by 1.3 folds as compared to control) as compared to the non-targeted
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formulation SPIONs@PAMAM-CDF (decreased by 1.19 folds as compared to
control), indicating a better anticancer activity of the targeted formulation. In case
of PTEN expression, western blot results showed a significantly low expression of
PTEN in control cells. However, there was an increase in PTEN expression in cells
treated with CDF and both of the formulations. Noticeably, PTEN level in cells
treated with the targeted formulation SPIONs@FA-PAMAM-CDF was higher than
CDF and the non-targeted formulation SPIONs@PAMAM-CDF. As compared to
control, PTEN expression was upregulated by 3.2 folds in HeLa treated with the
targeted formulation; whereas, in HeLa treated with free CDF and the non-targeted
formulation, PTEN expression was increased by 1.58 and 2.14 folds, respectively
[Fig 8]. The results suggested the ability of the targeted formulation SPIONs@FAPAMAM-CDF to upregulate PTEN and downregulate NF-κB, which is known to
play an important role in tumor suppressor activity and cancer cell death.

Summary
In this study, theranostic nanoparticles for cancer imaging and therapy were
successfully fabricated with SPIONs in the core and FA-PAMAM conjugates on
the periphery. To our knowledge, this is the first study employing a simple and
efficient carbodiimide coupling chemistry to fabricate SPIONs decorated PAMAM
dendrimers for MR imaging and targeted anticancer drug delivery. This fabrication
method could be used to encapsulate different types of hydrophobic anticancer
drugs for targeting MRI and therapy in various types of cancers by using
appropriate targeting molecules for specific recognition of unique biomarkers
overexpressed on cancer cells. In this study, the fabricated magnetic nanoparticles
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SPIONs@FA-PAMAM showed great potential to be a promising MR contrast agent
as well as an anticancer drug delivery system for CDF, a potent anticancer but
highly lipophilic compound. The targeted nanoparticles SPIONs@FA-PAMAM
possesses numerous favorable characteristics such as improved aqueous
solubility of CDF, biological safety and targeting ability to cancer cells due to the
presence of FA. As compared to SPIONs@PAMAM, SPIONs@FA-PAMAM
showed a better ability to enhance MR contrast with a faster cellular uptake in in
vitro T2-weighted images and fluorescence microscopic studies. In addition,
targeted formulation SPIONs@FA-PAMAM-CDF showed a higher anticancer
activity, a higher percentage of apoptotic and necrotic cells with the ability to
upregulate PTEN and downregulate NF-κB which could help overcome anticancer
drug resistance and the recurrence of cancer after initial treatment. The results
showed a promising potential of SPIONs@FA-PAMAM-CDF in targeted MRI and
therapy in cancer, warranting further in vivo investigations underway in our
laboratory.
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ABSTRACT
DENDRIMER-COATED IRON OXIDE THERANOSTIC NANOPARTICLES
FOR CANCER IMAGING AND THERAPY
by
Duy Luong
December 2016
Advisor: Dr. Arun Iyer
Major: Pharmaceutical Sciences
Degree: Master of Science
The bleak prognosis for patients diagnosed with metastatic cancer along
with the low therapeutic efficacy and the recurrence of cancer in conventional
chemotherapy are prompting clinical medicine to adopt a new strategy to detect
cancer in early stage and to deliver the anticancer drugs specifically to tumor site
to enhance therapeutic efficiency and minimize side effects. The aim of this study
is to design a theranostic nanocarrier consisting of iron oxide nanoparticles
(SPIONs) for magnetic resonance imaging (MRI) and Polyamidoamine dendrimers
conjugated with folic acid (FA-PAMAM) for active targeted delivery of a highly
potent but extremely lipophilic anticancer compound 3,4-difluorobenzylidene
diferuloylmethane (CDF). The resulting targeted nanoparticles SPIONs@FAPAMAM-CDF showed a significantly enhanced MR contrast as compared to the
non-targeted nanoparticles. When tested on SKOV3 (ovarian cancer cells) and
HeLa (cervical cancer cells), the targeted nanoformulations showed a higher
accumulation in cancer cells with a better anticancer activity, a larger population
of apoptotic cells and the ability to upregulate tumor suppressor phosphatase and
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tensin homolog (PTEN) and inhibit nuclear factor kappa B (NF-κB) which further
confirmed the ability of the folate decorated nanoparticles for targeted MRI and
anticancer drug delivery.

65

AUTOBIOGRAPHICAL STATEMENT
PUBLICATIONS
 D. Luong, P. Kesharwani, A.K. Iyer, Multifunctional dendrimer-coated iron
oxide theranostic nanoparticles for magnetic resonance imaging and active
targeting cancer cells, (Manuscript under preparation).
 P. Kesharwani, D. Luong, H. Alsaab, F.H. Sarkar, S. Padhye, A.K. Rishi, A.K.
Iyer, Folic acid decorated polymeric micelles loaded with 3,4difluorobenzylidene diferuloylmethane for targeting cervical and ovarian
cancers, (Under review).
 D. Luong, P. Kesharwani, B.A. Killinger, A. Moszczynska, F.H. Sarkar, S.
Padhye, A.K. Rishi, A.K. Iyer, Solubility enhancement and targeted delivery of
a potent anticancer flavonoid analogue to cancer cells using ligand decorated
dendrimer nano-architectures, J. Colloid Interface Sci. 484 (2016) 33–43.
 D. Luong, P. Kesharwani, R. Deshmukh, M.C.I. Mohd Amin, U. Gupta, K.
Greish, A.K. Iyer, PEGylated PAMAM dendrimers: Enhancing efficacy and
mitigating toxicity for effective anticancer drug and gene delivery., Acta
Biomater. (2016) 1–16.
 Nguyen Thanh Ha, Le Minh Tri, Nguyen Thien Hai, Duy Luong, Le Nguyen
Nguyet Minh, Ameliorate the solubility of Paclitaxel by forming the complex with
Hydroxypropyl-β-Cyclodextrin, Y Hoc TP. Ho Chi Minh. 18 (2014) 359-367.
PRESENTATIONS
 “Folic acid-decorated polymeric nanomicelles for targeted delivery of a potent
flavonoid analogue to folate receptors overexpressing cancers”, 2016
American Association of Pharmaceutical Scientists (AAPS) Annual Meeting
and Exposition, Colorado Convention Center, Denver, November 13 th – 17th
2016
 “Dendrimer-coated iron oxide nanoparticles for cancer imaging and therapy”,
Graduate Student Research Day, Wayne State University, Detroit, Michigan,
October 7th 2016
 “Multifunctional dendrimer-coated iron oxide theranostic nanoparticles for
magnetic resonance imaging and cancer therapy”, Annual Research Forum,
Wayne State University, Detroit, Michigan, October 5 th 2016
 “Folic acid decorated polymeric micelles loaded with 3,4-difluorobenzylidene
diferuloylmethane for targeting cervical and ovarian cancers”, Annual Research
Forum, Wayne State University, Detroit, Michigan, October 5 th 2016
 “Polyamidoamine dendrimer-coated superparamagnetic iron oxide theranostic
nanoparticles for targeted cancer therapy and imaging”, Cancer Metabolism
Symposium, University of Michigan, Ann Arbor, Michigan, May 25 th 2016
 “Dendrimer-coated iron oxide theranostic nanoparticles for cancer imaging and
therapy”, Annual Research Forum, Wayne State University, Detroit, Michigan,
November 4th 2015

